These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28476032)

  • 1. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
    Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
    Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
    PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
    Chewchuk S; Guo B; Parissenti AM
    PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
    Ponnusamy L; Mahalingaiah PKS; Singh KP
    Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
    Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in Cancer Stem Cells.
    Ashour F; Awwad MH; Sharawy HEL; Kamal M
    J Egypt Natl Canc Inst; 2018 Jun; 30(2):45-48. PubMed ID: 29779937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
    Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
    Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
    Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
    Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.